Article Information
History
- January 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Daniel Junker1,*,
- Matthias Becker1,*,
- Teresa R. Wagner1,2,*,
- Philipp D. Kaiser1,
- Sandra Maier1,
- Tanja M. Grimm1,
- Johanna Griesbaum1,
- Patrick Marsall1,
- Jens Gruber1,
- Bjoern Traenkle1,
- Constanze Heinzel3,
- Yudi T. Pinilla3,
- Jana Held3,
- Rolf Fendel3,4,5,
- Andrea Kreidenweiss3,4,5,
- Annika Nelde6,7,8,
- Yacine Maringer6,7,8,
- Sarah Schroeder7,9,
- Juliane S. Walz6,7,8,10,
- Karina Althaus11,12,
- Gunalp Uzun11,
- Marco Mikus11,
- Tamam Bakchoul11,12,
- Katja Schenke-Layland1,8,13,14,
- Stefanie Bunk15,
- Helene Haeberle16,
- Siri Göpel4,15,
- Michael Bitzer15,17,
- Hanna Renk18,
- Jonathan Remppis18,
- Corinna Engel18,19,
- Axel R. Franz18,19,
- Manuela Harries20,
- Barbora Kessel20,
- Monika Strengert20,21,
- Gerard Krause20,21,
- Anne Zeck1,
- Ulrich Rothbauer1,2,
- Alex Dulovic1,§,# and
- Nicole Schneiderhan-Marra1,§,#
- 1NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany
- 2Pharmaceutical Biotechnology, University of Tuebingen, Tuebingen, Germany
- 3Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany
- 4German Center for Infection Research (DZIF), Partner Site Tuebingen, Tuebingen, Germany
- 5Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon
- 6Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany
- 7Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany
- 8Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, Germany
- 9Department of Otolaryngology, Head and Neck Surgery, University of Tuebingen, Tuebingen, Germany
- 10Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany
- 11Center for Clinical Transfusion Medicine, Tuebingen, Germany
- 12Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Tuebingen, Germany
- 13Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, University of Tuebingen, Tuebingen, Germany
- 14Department of Medicine/Cardiology, University of California Los Angeles (UCLA), Los Angeles, USA
- 15Infectious Diseases, Department Internal Medicine I, University Hospital Tuebingen, Tuebingen, Germany
- 16Department of Anaesthesiology and Intensive Care Medicine, University Hospital Tuebingen, Tuebingen, Germany
- 17Center for Personalized Medicine, University of Tuebingen, Tuebingen, Germany
- 18University Children’s Hospital, Tuebingen, Germany
- 19Center for Pediatric Clinical Studies, University Hospital Tuebingen, Tuebingen, Germany
- 20Helmholtz Center for Infection Research, Braunschweig, Germany
- 21TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
- ↵#indicates corresponding author Corresponding author Information
Alex Dulovic – alex.dulovic{at}nmi.de, +49 (0)7121 51530 580, Nicole Schneiderhan-Marra – nicole.schneiderhan{at}nmi.de, +49 (0)7121 51530 815
Posted January 01, 2022.
Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern
